Clinical Trials Logo

Filter by:
NCT ID: NCT04240886 Terminated - Clinical trials for Invasive Fungal Infections

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

AEGIS
Start date: January 4, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).

NCT ID: NCT04240574 Terminated - Diabetic Foot Ulcer Clinical Trials

Debritom - Micro Water Jet Technology and Wound Healing

Start date: January 24, 2020
Phase: N/A
Study type: Interventional

This study will investigate the clinical efficacy of micro water jet technology in the debridement and healing of chronic lower extremity ulcers.

NCT ID: NCT04240483 Terminated - Low Back Pain Clinical Trials

Intracutaneous Sterile Water Injections for Acute Low Back Pain in the Emergency Department

Start date: July 27, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of intracutaneous sterile water injections (ISWI) for treatment of acute low back pain in patients presenting to the emergency department. The primary aim is to determine if ISWI provides pain relief for acute low back pain in the ED. The secondary aim is to evaluate whether ISWI provides improved patient satisfaction in the ED setting. The hypothesis is that ISWI will improve pain amongst patients presenting with acute low back pain to the ED.

NCT ID: NCT04240457 Terminated - Keratoconus Clinical Trials

Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions

Start date: July 8, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of the PXL Platinum 330 device for performing Corneal Crosslinking in patients with corneal thinning conditions.

NCT ID: NCT04240210 Terminated - Clinical trials for Human Immunodeficiency Virus

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

SymITA
Start date: September 17, 2019
Phase: Phase 4
Study type: Interventional

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COB/FTC/TAF) is a coformulated STR, is the only protease inhibitor based STR, and is noted for its high tolerability3. These traits have the potential to improve adherence in patients who have intolerance to the integrase inhibitor class. We propose a two part study design to evaluate if patients who have suboptimal adherence due to integrase inhibitor intolerance may better tolerate Symtuza and subsequently have improved adherence.

NCT ID: NCT04239261 Terminated - Mucositis Clinical Trials

Serum-derived Bovine Immunoglobulin Effect on Mucositis

Start date: January 17, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this cancer control clinical research study is to evaluate whether nutritional therapy with Serum-derived bovine immunoglobulin/protein isolate (SBI) might reduce mucositis (a condition caused by cancer treatment involving mouth sores, pain and/or bleeding that may cause difficulty eating), improve nutritional status and lessen the symptoms associated with chemo-radiation therapy which may result in quality of life (QOL) improvements during the prescribed treatment for cancer therapy.

NCT ID: NCT04238013 Terminated - Clinical trials for Spinal Cord Injuries

Neuromodulation of Ankle Muscles in Persons With SCI

Start date: July 6, 2021
Phase: N/A
Study type: Interventional

The ability to voluntarily move the ankles is important for walking. After spinal cord injury (SCI), this ability is impaired because of changes in the communication between the brain, spinal cord, and body. Whole body vibration (WBV) is a treatment that increases voluntary muscle control and decreases uncontrollable muscle movement in people with SCI. The purpose of this study is to understand how WBV can impact ankle control and uncontrollable muscle movement.

NCT ID: NCT04237649 Terminated - Solid Tumors Clinical Trials

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Start date: February 20, 2020
Phase: Early Phase 1
Study type: Interventional

The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.

NCT ID: NCT04237584 Terminated - Clinical trials for Metastatic Castration-resistant Prostate Cancer

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

ESCALATE
Start date: June 30, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.

NCT ID: NCT04235660 Terminated - Clinical trials for Hepatocellular Carcinoma (HCC)

Y90 Radiation Segmentectomy vs SBRT for HCC

SBRT vs Y90
Start date: July 22, 2020
Phase: N/A
Study type: Interventional

The proposed study is a single site, prospective, randomized pilot study to assess the feasibility of recruitment of patients into a trial evaluating the efficacy and tolerability of selective transarterial Y90 radioembolization (radiation segmentectomy) versus stereotactic body radiation therapy (SBRT) for solitary early stage (≤ 3cm) hepatocellular carcinoma (HCC).